For HCPs > Overview

A friendly face at every step

Connect your patient with dedicated support.

Amicus AssistTM is a service designed to provide product assistance and support for Galafold® (migalastat).* As part of the program, you and your patient will be assigned a dedicated case manager.

Download referral form

Your dedicated case manager

Get personalized support for you and your patient.

Contact us toll-free

1-833-AMICUS-A (1-833-264-2872) | Monday through Friday, 8AM to 8PM ET

Contact us toll-free

1-833-AMICUS-A (1-833-264-2872)
Monday through Friday, 8AM to 8PM ET

Case Managers

We are committed to helping your patient access Galafold®. A dedicated case manager will be assigned to your patient if they have been prescribed an Amicus medication and who enroll in the program. Case managers are available to:

  • Verify and explain insurance coverage
  • Assist with the prior authorization process
  • Help with the coordination of delivery of your patient’s therapy
  • Identify possible financial assistance
  • Provide ongoing support throughout their treatment journey

*Patients must be prescribed Galafold for an approved indication to be eligible for support from Amicus Assist.

The path to therapy

See how Amicus Assist can help along the way

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

Galafold® (migalastat) is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
The most common adverse drug reactions reported with Galafold (≥10 %) are headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia.

Use in Specific Populations
There is insufficient clinical data on Galafold use in pregnant women to inform a drug associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.

It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.

Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.

The safety and effectiveness of Galafold have not been established in pediatric patients.

To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for Full Prescribing Information.

Referral Form